Natural products demonstrate multitarget therapeutic potential for treating diabetic cardiomyopathy by alleviating oxidative stress, inflammation, and myocardial fibrosis across various preclinical models.
Natural products offer a promising multitarget therapeutic approach for the prevention and treatment of diabetic cardiomyopathy by modulating oxidative stress, inflammation, and apoptosis.
Diabetic cardiomyopathy (DCM), a diabetes-specific cardiovascular complication, is pathologically characterized by cardiomyocyte apoptosis, oxidative stress, inflammatory responses, and myocardial fibrosis, distinguishing it from other cardiac disorders, such as hypertension and coronary artery disease. Challenges in early diagnosis, coupled with the limited efficacy and adverse effects of current treatments, have made DCM a significant contributor to heart failure and mortality in patients with diabetes. Natural products, recognized for their diverse sources, structural variety, and multitarget therapeutic potential, have shown promise in preventing and treating DCM. Drawing on advances over the past five years, this review systematically summarizes the pharmacological effects and molecular mechanisms of natural products (e.g., flavonoids, terpenoids, phenylpropanoids, alkaloids, and polysaccharides) in the treatment of DCM, with the aim of providing a theoretical foundation for further research and drug development.
Zhao et al. (Fri,) conducted a review in Diabetic cardiomyopathy. Natural products (flavonoids, terpenoids, phenylpropanoids, alkaloids, polysaccharides) was evaluated. Natural products demonstrate multitarget therapeutic potential for treating diabetic cardiomyopathy by alleviating oxidative stress, inflammation, and myocardial fibrosis across various preclinical models.